ABIVAX, a clinical stage biotechnology company, recently completed a successful first-in-man Phase 1 study of ABX464, which may prevent the replication of the virus that causes AIDS.
Preliminary studies found that the molecule is the first treatment that continues reducing HIV even after regular doses have stopped.
Phase 1 testing measured the success of ABX464 when given to healthy volunteers. The study included 4 doses of the drug in 50, 100, 150 and 200mg doses.
Researchers studied the biological safety of the drug and its pharmacokinetic properties, and recorded that there were no serious side effects or abnormal results when they analyzed the vital signs, laboratory test results, ECG and physical exams of the study subjects.
Phase 2 of the study on patients with HIV is scheduled to begin soon.
"We are very pleased with the results of the first-in-man study of ABX464,” Dr. Hartmut Ehrlich, CEO of ABIVAX, said. “ABX464 is one of our flagship products currently under development, and these results pave the way for the upcoming launch of our Phase 2 study. We are confident that ABX464, with its unique properties and mode of action, has the potential to induce a long-lasting control of the virus for the benefit of the more than 35 million people worldwide living with HIV."